This is the third edition of our newsletter titled HER2-Positive Breast Cancer Updates. In this issue, we provide highlights that emanated from Perspectives in the Management of HER2-Positive Breast Cancer, a recent roundtable discussion held at the West Cancer Center in Memphis, Tennessee. Panelists discussed current topics such as neoadjuvant therapy and the emerging utilization of pathologic complete response rate. This edition also provides articles on topics such as the benefit of neoadjuvant therapy in early-stage HER2-postive breast cancer, the association of total pathologic complete response (tpCR) with event-free survival in HER-2 positive early breast cancer, and the role of the nurse practitioner in advancing patient care. Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at email@example.com.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.
Heather Greene, MSN, FNP, AOCN®
The West Cancer Center